Advanced Urothelial Cancer
Conditions
Brief summary
The primary endpoint is overall survival (OS). Overall survival is measured from the date of randomization to the date of the subject's death. If the subject is alive or the vital status is unknown, the subject will be censored at the date the subject was last known to be alive
Interventions
DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion
DRUGJNJ-42756493
DRUGDocetaxel-ratiopharm 20mg/ml Konzentrat zur Herstellung einer Infusionslösung
Sponsors
Janssen Cilag International
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is overall survival (OS). Overall survival is measured from the date of randomization to the date of the subject's death. If the subject is alive or the vital status is unknown, the subject will be censored at the date the subject was last known to be alive | — |
Countries
Belgium, France, Spain
Outcome results
None listed